

Novel Bi-Specific Immuno-Modulatory Tribodies Potentiate T Cell Activation And Increase Anti-Tumor Efficacy

Margherita Passariello^{1,2}, Asami Yoshioka³, Kota Takahashi³, Shu-ichi Hashimoto³, Rosa Rapuano Lembo^{2,4}, Lorenzo Manna^{1,2}, Koji Nakamura³ and Claudia De Lorenzo^{1,2*}

1 Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", 80131 Naples, Italy

2 Ceinge - Biotechnologie Avanzate s.c. a.r.l., via Gaetano Salvatore 486, 80145 Naples, Italy

3 Chiome Bioscience Inc, 3-12-1 Hommachi Shibuya-Ku, Tokyo 151-0071 Japan

4 European School of Molecular Medicine, University of Milan, 20122 Milan, Italy

* Correspondence: cladelor@unina.it; Tel.: +39-081-3737868

Supplementary Figures and Legends




Figure S1. SEC Analysis. The analysis of the purified samples to verify the stability of tribodies was also performed after storage at 4°C for up to 4 weeks.




Figure S2. Representative images of MDA-MB-231 cells co-cultured with hPBMCs and treated with the indicated tribodies.